Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | Director · Executive Chair | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 302,214 |
Last balance in matching sequence
After 2026-08-20 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-08-20 · Sale · Disposed 19,308 · Balance 309,662 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2: This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Row 2 · 2026-08-20 · Sale · Disposed 7,351 · Balance 302,311 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F4: This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Row 3 · 2026-08-20 · Sale · Disposed 97 · Balance 302,214 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
F2: This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
F4: This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 29, 2020 Filed Oct 30, 2020 21:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,428 | $336.43 | $816,859.57 |
DisclosureSEC source: 0001093557-20-000300 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,639 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $335.98 to $336.935. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 56,792 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 17,915 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 13,424 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 21:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,910 | $335.53 | $976,387.94 |
DisclosureSEC source: 0001093557-20-000300 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,067 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $334.94 to $335.89. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 56,792 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 17,915 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 13,424 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 21:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $333.63 | $200,176.38 |
DisclosureSEC source: 0001093557-20-000300 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,977 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $333.282 to $334.22. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 56,792 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 17,915 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 13,424 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,068 | $398.30 | $1,221,990.54 |
DisclosureSEC source: 0001093557-20-000255 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,577 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 56,792 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 17,915 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 13,424 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,897 | $398.30 | $2,747,088.89 |
DisclosureSEC source: 0001093557-20-000255 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,645 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 56,792 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 17,915 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 13,424 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $426.24 | $85,247.00 |
DisclosureSEC source: 0001093557-20-000199 · edgardoc.xml · nonDerivative · entry 9 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,542 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $426.18 to $426.29. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,476 | $424.85 | $627,084.06 |
DisclosureSEC source: 0001093557-20-000199 · edgardoc.xml · nonDerivative · entry 8 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,742 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $424.54 to $425.015. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,049 | $423.64 | $444,395.53 |
DisclosureSEC source: 0001093557-20-000199 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,218 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $423.50 to $424.48. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 400 | $422.71 | $169,082.00 |
DisclosureSEC source: 0001093557-20-000199 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,267 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $422.47 to $422.94. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,222 | $421.86 | $515,509.13 |
DisclosureSEC source: 0001093557-20-000199 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,667 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $421.24 to $422.20. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $419.91 | $209,957.00 |
DisclosureSEC source: 0001093557-20-000199 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,889 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $419.37 to $420.12. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $413.98 | $41,398.00 |
DisclosureSEC source: 0001093557-20-000199 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,389 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 653 | $412.62 | $269,441.58 |
DisclosureSEC source: 0001093557-20-000199 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,489 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $412.20 to $412.71. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 400 | $408.87 | $163,547.60 |
DisclosureSEC source: 0001093557-20-000199 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,142 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $381.80 | $76,360.00 |
DisclosureSEC source: 0001093557-20-000179 · edgardoc.xml · nonDerivative · entry 9 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,542 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $381.61 to $381.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $381.01 | $190,507.25 |
DisclosureSEC source: 0001093557-20-000179 · edgardoc.xml · nonDerivative · entry 8 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,742 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $380.44 to $381.20. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 374 | $379.49 | $141,930.01 |
DisclosureSEC source: 0001093557-20-000179 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,242 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $379.15 to $380.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 400 | $378.07 | $151,229.00 |
DisclosureSEC source: 0001093557-20-000179 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,616 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $377.945 to $378.23. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,058 | $376.93 | $398,787.39 |
DisclosureSEC source: 0001093557-20-000179 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,016 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $376.55 to $377.33. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,400 | $375.93 | $526,304.52 |
DisclosureSEC source: 0001093557-20-000179 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,074 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $375.53 to $376.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,418 | $374.91 | $531,618.41 |
DisclosureSEC source: 0001093557-20-000179 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,474 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $374.515 to $375.37. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 400 | $373.87 | $149,546.52 |
DisclosureSEC source: 0001093557-20-000179 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,892 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $373.31 to $374.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $372.47 | $93,116.50 |
DisclosureSEC source: 0001093557-20-000179 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,292 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $372.04 to $372.58. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| May 04, 2020 Filed May 7, 2020 00:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 400 | $347.68 | $139,070.00 |
DisclosureSEC source: 0001093557-20-000143 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,542 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $347.49 to $347.86. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| May 04, 2020 Filed May 7, 2020 00:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,200 | $346.73 | $416,079.96 |
DisclosureSEC source: 0001093557-20-000143 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,942 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $346.40 to $347.04. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| May 04, 2020 Filed May 7, 2020 00:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 794 | $345.46 | $274,293.02 |
DisclosureSEC source: 0001093557-20-000143 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,142 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $344.99 to $345.82. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| May 04, 2020 Filed May 7, 2020 00:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,587 | $344.51 | $546,730.23 |
DisclosureSEC source: 0001093557-20-000143 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,936 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $343.99 to $344.96. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| May 04, 2020 Filed May 7, 2020 00:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,219 | $343.46 | $418,672.50 |
DisclosureSEC source: 0001093557-20-000143 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,523 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $342.98 to $343.86. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| May 04, 2020 Filed May 7, 2020 00:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 300 | $341.71 | $102,513.99 |
DisclosureSEC source: 0001093557-20-000143 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,742 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $341.58 to $341.98. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| May 04, 2020 Filed May 7, 2020 00:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $340.80 | $170,401.00 |
DisclosureSEC source: 0001093557-20-000143 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,042 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $340.43 to $341.07. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $279.99 | $55,998.00 |
DisclosureSEC source: 0001093557-20-000118 · edgardoc.xml · nonDerivative · entry 12 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,542 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 66 | $274.88 | $18,142.08 |
DisclosureSEC source: 0001093557-20-000118 · edgardoc.xml · nonDerivative · entry 11 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,742 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $268.93 | $26,893.00 |
DisclosureSEC source: 0001093557-20-000118 · edgardoc.xml · nonDerivative · entry 10 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,808 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 300 | $266.46 | $79,937.01 |
DisclosureSEC source: 0001093557-20-000118 · edgardoc.xml · nonDerivative · entry 9 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,908 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $266.30 to $266.77. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $265.37 | $132,683.00 |
DisclosureSEC source: 0001093557-20-000118 · edgardoc.xml · nonDerivative · entry 8 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,208 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $265.29 to $265.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 802 | $264.22 | $211,903.72 |
DisclosureSEC source: 0001093557-20-000118 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,708 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $264.09 to $264.795. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $263.08 | $157,845.00 |
DisclosureSEC source: 0001093557-20-000118 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,510 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $263.04 to $263.11. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,000 | $262.37 | $262,365.00 |
DisclosureSEC source: 0001093557-20-000118 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,110 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $261.83 to $262.73. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $261.34 | $130,671.00 |
DisclosureSEC source: 0001093557-20-000118 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,110 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $260.83 to $261.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 900 | $260.13 | $234,118.98 |
DisclosureSEC source: 0001093557-20-000118 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,610 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $259.64 to $260.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 332 | $258.48 | $85,814.99 |
DisclosureSEC source: 0001093557-20-000118 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,510 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $258.39 to $258.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 700 | $257.81 | $180,467.00 |
DisclosureSEC source: 0001093557-20-000118 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,842 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $257.22 to $258.13. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 13,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-20-000093 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,542 F5 · shares: The transaction represents a gift by the Reporting Person of 13,474 shares to a charitable donor advised fund. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 19,570 | $265.43 | $5,194,386.82 |
DisclosureSEC source: 0001093557-20-000093 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,016 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 796 | $250.09 | $199,074.59 |
DisclosureSEC source: 0001093557-20-000093 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,586 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $250.02 to $250.152. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 8 | $246.27 | $1,970.18 |
DisclosureSEC source: 0001093557-20-000093 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,382 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $246.1339 to $246.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 120 | $273.05 | $32,766.50 |
DisclosureSEC source: 0001093557-20-000065 · edgardoc.xml · nonDerivative · entry 11 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,390 F3 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $273.025 to $273.06. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,276 | $272.51 | $620,242.09 |
DisclosureSEC source: 0001093557-20-000065 · edgardoc.xml · nonDerivative · entry 10 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,510 F3 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $272.00 to $272.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $271.46 | $54,292.00 |
DisclosureSEC source: 0001093557-20-000065 · edgardoc.xml · nonDerivative · entry 9 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,786 F3 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $271.00 to $271.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $269.00 | $67,250.00 |
DisclosureSEC source: 0001093557-20-000065 · edgardoc.xml · nonDerivative · entry 8 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,986 F3 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.